GET DAILY SIGNALSWhy Is Diebold Nixdorf (DBD) Stock Down -9.90% Today?
Key Takeaways
- DBD shares fell roughly 9.9% in Wednesday's session after the company reported third-quarter results and cut its full-year outlook.
- The primary catalyst was lowered 2026 guidance, with adjusted EPS now expected at $4.50–$4.85 versus a prior $5.25–$5.75.
- Third-quarter GAAP earnings declined sharply year over year, with EPS of $0.19 compared with $1.11 a year earlier.
- Management cited revenue mix and raw-material cost pressures as the drivers behind the reduced profitability outlook.
- A newly authorized $250 million share repurchase program provided a partial offset but failed to steady the shares.
- Traders are watching the company's investor call and updated cash-flow expectations for further clarity on margins.
- For deeper data on this stock, explore Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies for thousands of tickers on the Trending AI Robots page.
Opening Summary
Diebold Nixdorf, Incorporated (DBD), a global provider of ATMs, self-service banking technology, point-of-sale systems, and related software and services for the banking and retail industries, saw its stock slide sharply on Wednesday. Shares were down about 9.9%, trading near $60.08, after closing the prior session at $66.68. The selloff followed the company's third-quarter 2026 earnings release, in which solid revenue growth was overshadowed by a decline in net income and a downward revision to full-year profit guidance.
Earnings Results and Guidance Cut
The market reaction was driven primarily by the company's updated financial outlook. DBD reported third-quarter revenue of approximately $994.3 million, up about 5% year over year, led by continued double-digit growth in its Retail segment. However, GAAP net income fell roughly 84% to about $6.6 million, with diluted earnings per share of $0.19 versus $1.11 in the prior-year quarter.
More consequential for investors was the guidance revision. The company lowered its full-year 2026 adjusted EPS outlook to a range of $4.50 to $4.85, down from a prior range of $5.25 to $5.75. It also trimmed the top end of its revenue guidance to $3.86 billion to $3.90 billion and reduced its adjusted EBITDA forecast to $490 million to $510 million, from a previous $510 million to $535 million. Full-year free cash flow guidance was cut to $190 million to $210 million from $255 million to $270 million.
Margin and Cost Pressures
Management attributed the softer outlook to an unfavorable product and revenue mix alongside raw-material cost pressures, partially offset by productivity improvements and operating-expense discipline. The company also flagged that it is expected to become a cash taxpayer in Germany going forward, which weighed on its revised free cash flow projection. These factors raised concerns that margin momentum could lag even as revenue continues to expand.
Market Context and Trading Activity
The decline was amplified by an earnings-driven surge in trading volume relative to the stock's recent average, reflecting heavy repositioning by investors responding to the revised outlook. The move was largely company-specific, diverging from a broader market that was not uniformly lower, underscoring that the selloff was tied to DBD's own results rather than broad index weakness. The drop also pushed the shares back toward the lower portion of their recent trading range after a period of relative stability above the mid-$60s.
What Comes Next for DBD
Investors will be focused on management's commentary during the earnings call, particularly around the sustainability of Retail growth, the trajectory of raw-material costs, and whether the lower guidance proves conservative. The newly authorized $250 million share repurchase program may provide some support, but questions about margin recovery and cash-flow conversion are likely to dominate sentiment in the near term. Risks include ongoing cost inflation, shifting product mix, and execution on strategic initiatives as the company closes out the fiscal year.
Trending AI Robots
Tickeron's Trending AI Robots page highlights AI-powered trading bots that are currently performing strongly under prevailing market conditions. Tickeron offers hundreds of bots covering thousands of tickers, but only the top performers are featured in this curated section. The bots vary by strategy, timeframe, performance metrics, and traded symbols. Explore the Trending AI Robots page to see which strategies are leading the market right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DBD in upward trend: price rose above 50-day moving average on October 15, 2026
DBD moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on DBD as a result. In 42 of 53 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for DBD just turned positive on October 01, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in 23 of 32 cases over the following month. The odds of a continued upward trend are 72%.
The 10-day moving average for DBD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBD advanced for three days, in 174 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for DBD moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 21 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for DBD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. DBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.335) is normal, around the industry mean (-0.834). P/E Ratio (21.791) is within average values for comparable stocks, (15.481). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.077) among similar stocks. P/S Ratio (0.606) is also within normal values, averaging (71.128).
The Tickeron SMR rating for this company is 67 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware
Advertisement